Rasna Therapeutics (QB) Stock Price

0.00 (0.0%)


52 Week Range


Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Rasna Therapeutics Inc (QB) RASP OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.05 09:18:16
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
0.03 0.065 0.035 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.05 USD


Draw Mode:

Rasna Therapeutics Inc (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.45M 68.91M 9.38M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
360.00 $ - - - -

more financials information »

Rasna Therapeutics (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RASP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.,0000.000.0%
1 Month0.0750.0750.050.05227275,500-0.025-33.33%
3 Months0.09990.1350.0250.06463333,095-0.0499-49.95%
6 Months0.050.180.0250.07009248,8860.000.0%
1 Year0.01030.330.01030.05574248,1480.0397385.44%
3 Years1.001.000.01030.069964839,058-0.95-95.0%
5 Years1.1010.000.00030.192501824,350-1.05-95.45%

Rasna Therapeutics (QB) Description

Rasna Therapeutics, Inc. (OTC:RASP), a development stage biotechnology company focused on the development of cancer drugs, today announced the successful completion of its merger. Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the development of drug candidates for leukemia and lymphoma. Abnormal epigenetic modification is recognized to play an important role in the pathogenesis of acute myeloid leukemia (AML), leading to silencing of genes involved in tumor suppression and cellular reproduction. Rasna's focus on inhibition of lysine specific demethylase-1 (LSD1), an enzyme involved in epigenetic control, represents a promising and novel approach towards AML. Rasna has developed novel irreversible and reversible LSD1 regulators that have shown appropriate effects on the LSD1 gene in-vitro and in IND-enabling pre-clinical studies.

Your Recent History
Rasna Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.